Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May-Jun;22(3):308-315.
doi: 10.4103/ijem.IJEM_446_17.

Neuroendocrine Neoplasms in Rare Locations: Clinicopathological Features and Review of the Literature

Cristina Díaz Del Arco  1 , Javier Sastre  2 , Paloma Peinado  2 , Ángel Díaz  3 , Luis Ortega Medina  1 , Mª Jesús Fernández Aceñero  1
Affiliations

Neuroendocrine Neoplasms in Rare Locations: Clinicopathological Features and Review of the Literature

Cristina Díaz Del Arco et al. Indian J Endocrinol Metab. 2018 May-Jun.

Abstract

Introduction: Neuroendocrine tumors (NETs) occur more often in lungs, gastrointestinal tract, or pancreas. Data about terminology and grading of NETs in rare locations are scarce and variable, and they have been reported mainly as case reports.

Materials and methods: We here describe our experience with NETs in unusual locations. We have reviewed all NETs diagnosed in our institution and summarized their clinicopathological features. We have also reviewed the literature and discussed the main characteristics of NETs in each site.

Results: Two hundred and forty-three primary NETs were diagnosed. About 55.2% of patients were men and the mean age was 62 years. About 90.7% of NETs were located in lungs, gastrointestinal tract, or pancreas, and 50.8% of them were low-grade tumors. We identified 13 NETs in rare locations: breast, ovary, endometrium, vulva, uterine cervix, extrahepatic biliary tract, kidney, sinonasal tract, and thymus. Three additional tumors were diagnosed by the senior author in other institution. Patients were asymptomatic or presented with nonspecific symptoms. All NETs were treated with surgery and 31% of patients received adjuvant therapy. There were 10 Grade 3 (62.5%), 2 Grade 2 (12.5%), and 4 Grade 1 (25%) tumors. Mean follow-up was 72 months. About 60% of G3 tumors recurred or progressed. G2 tumors were located in breast, and both patients are stable. About 50% of G1 tumors recurred or progressed (both renal NETs).

Conclusions: NETs in rare locations are heterogeneous, and their behavior does not seem to correlate absolutely with tumor grade. More studies are needed to clarify the role of proliferation rate in these tumors.

Keywords: Classification; grade; location; neuroendocrine; rare.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Neuroendocrine tumor of the kidney (G1). H and E, ×200
Figure 2
Figure 2
(a) Strong and diffuse expression of synaptophysin. Neuroendocrine tumor of the kidney (G1). Synaptophysin, ×100. (b) Ki-67 of <2%. Neuroendocrine tumor of the kidney (G1). Ki-67, ×200
See this image and copyright information in PMC

References

    1. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, et al. Pathology reporting of neuroendocrine tumors: Application of the delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300–13. - PubMed
    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. - PubMed
    1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813–29. - PubMed
    1. Kunz PL. Carcinoid and neuroendocrine tumors: Building on success. J Clin Oncol. 2015;33:1855–63. - PubMed
    1. Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N, et al. Pancreatic neuroendocrine tumors: A review. Future Oncol. 2015;11:853–64. - PubMed